Bristol Myers Squibb shared on LinkedIn:
“Next month, we’re presenting at ASH 2026 where we’ll share new research spanning our hematology portfolio.
From CELMoDs and cell therapies to novel combinations, our latest data reflect the breadth of our scientific approach and our commitment to advancing treatment possibilities for people living with hematologic disease.
With 92 scientific disclosures across multiple myeloma, lymphoma and other hematologic diseases, we’re looking forward to sharing the science and engaging with the hematology community in New Orleans.
Explore what we’re bringing to ASH 2026:”
Key Highlights from ASH 2026
- Bristol Myers Squibb will present more than 90 scientific disclosures, including 24 oral presentations, at the 68th American Society of Hematology Annual Meeting in New Orleans, December 12–15, 2026.
- Multiple myeloma presentations include Phase 3 EXCALIBER-RRMM results for iberdomide (ZENBEXUS) with daratumumab and dexamethasone, plus SUCCESSOR-2 data on mezigdomide combinations. Early-phase research covers dual-targeting BCMA×GPRC5D CAR T therapy tunlucabtagene autoleucel, GPRC5D-directed arlocabtagene autoleucel, and combinations involving mezigdomide and elranatamab in relapsed or refractory disease, including heavily pretreated patient populations.
- In lymphoma, BMS will report Phase 2 GOLSEEK-2 findings for golcadomide plus rituximab in newly diagnosed advanced follicular lymphoma, alongside five-year Phase 3 TRANSFORM follow-up for lisocabtagene maraleucel (Breyanzi) in second-line large B-cell lymphoma. Additional presentations assess real-world comparisons with bispecific antibodies and investigational protein degraders in follicular lymphoma research.
- Myeloid-disorder research includes Phase 2 luspatercept (Reblozyl) data in adults with non-transfusion-dependent alpha-thalassemia hemoglobin H disease and Phase 2a results in adolescents with transfusion-dependent beta-thalassemia.
- The broader program also includes analyses in myelodysplastic syndromes and myelofibrosis, reflecting BMS’s efforts across rare hematologic disorders and blood cancers.
Proceed to the video attached to the post:
You may also be interested in:
Bristol Myers Squibb to Present New Multiple Myeloma and Lymphoma Data at ASH 2026
Bristol Myers Squibb Unifies R&D Under Cristian Massacesi in Major Leadership Restructuring
Talha Badar: Menin Inhibitors at ASH 2026 Across AML Treatment